Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2022 Jul 19:13:868298.
doi: 10.3389/fendo.2022.868298. eCollection 2022.

Sarcopenic Obesity in Individuals With Neurodisabilities: The SarcObeNDS Study

Yannis Dionyssiotis  1   2   3 , Konstantinos Prokopidis  4 , George Trovas  2 , Maria-Christina Papadatou  2   3 , Nikolaos Ananidis  3 , Vasileios Tragoulias  3 , Eleni Lazarou  5 , Evangelia Christaki  5 , Marilena Domazou  5 , Antonios Galanos  2 , Minos Tyllianakis  1
Affiliations
Observational Study

Sarcopenic Obesity in Individuals With Neurodisabilities: The SarcObeNDS Study

Yannis Dionyssiotis et al. Front Endocrinol (Lausanne). .

Abstract

Introduction: Patients with neurodisabilities (NDS) are prone to alterations in body composition. Sarcopenic obesity (SO) is a condition characterized by increased adipose tissue accompanied by sarcopenia. The aim of this study was to investigate the prevalence of SO in patients with NDS, including stroke, spinal cord, and traumatic brain injuries.

Methods: The study Sarcopenic Obesity in NeuroDisabled Subjects (acronym: SarcObeNDS) was a cross-sectional study of hospitalized patients (n = 82) and healthy controls (n = 32) with a mean age of 60.00 ± 14.22 years old. SO and sarcopenia were assessed through total body fat % (TBF %), fat mass index (fat mass to height2: FMI = FM/h2; kg/m2), and skeletal muscle index (appendicular skeletal muscle to height2: SMI = ASM/h2; kg/m2) via full-body dual-energy X-ray absorptiometry (DXA). This study was registered in the international database ClinicalTrials.gov with the unique identification number NCT03863379.

Results: A statistically significant difference was found in SMI (7.18 ± 0.95 vs. 6.00 ± 1.13 kg/m2, p < 0.001) between controls and patients with NDS. No statistical significance was found for TBF (p = 0.783) and FMI (p = 0.143) between groups. The results remained the same after controlling the results for gender and BMI. A strong positive correlation was demonstrated between BMI and TBF for the total population (r = 0.616, p < 0.001), the control group (r = 0.616, p < 0.001), and patients with NDS (r = 0.728, p < 0.001).

Conclusion: In summary, we observed significantly lower BMI and SMI scores in both genders compared to healthy controls. At the clinical level, a timely diagnosis and rapid treatment of sarcopenia and/or obesity in this population may prevent further metabolic repercussions accompanied by higher functional decline and lower quality of life.

Keywords: sarcopenia; sarcopenic obesity; skeletal mass index; spinal cord injury; stroke; traumatic brain injury.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Flowchart of the screening process for the selection of included participants.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Dionyssiotis Y. Body Composition in Disabilities of Central Nervous System, Dual Energy X-Ray Absorptiometry. In: Maghraoui, AE, editor. (2012).
    1. Wilkinson DJ, Piasecki M, Atherton PJ. The Age-Related Loss of Skeletal Muscle Mass and Function: Measurement and Physiology of Muscle Fibre Atrophy and Muscle Fibre Loss in Humans. Ageing Res Rev (2018) 47:123–32. doi: 10.1016/j.arr.2018.07.005 - DOI - PMC - PubMed
    1. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. . Sarcopenia: Revised European Consensus on Definition and Diagnosis. Age Ageing (2019) 48:16–31. doi: 10.1093/ageing/afy169 - DOI - PMC - PubMed
    1. Shafiee G, Keshtkar A, Soltani A, Ahadi Z, Larijani B, Heshmat R, et al. . Prevalence of Sarcopenia in the World: A Systematic Review and Meta-Analysis of General Population Studies. J Diabetes Metab Disord (2017) 16:1–10. doi: 10.1186/s40200-017-0302-x - DOI - PMC - PubMed
    1. Barazzoni R, Bischoff S, Boirie Y, Busetto L, Cederholm T, Dicker D, et al. . Sarcopenic Obesity: Time to Meet the Challenge. Obes Facts (2018) 11:294–305. doi: 10.1159/000490361 - DOI - PMC - PubMed

Publication types

Associated data